PharmAla Biotech (QB)【MDXXF】銘柄情報

PharmAla Biotech Holdings Inc (QB) (MDXXF) 銘柄情報

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

プレミアム

通貨

0.0998

( 0.10% )

買値

0.0059

売値

0.1317

出来高

1,025

0.0998 日の範囲 0.0998

0.0614 52 週間の範囲 0.1511

時価総額

10.867M

前日終値

0.0997

始値

0.0998

時刻

0.0921

最終取引時間

財務取引量

US$ 102

VWAP

0.0998

平均取引量 (3 か月)

US$ 212,077

発行済株式数

108,887,215

配当利回り

PER

-9.03

1 株当たり利益 (EPS)

-0.02

歳入

889.57k

純利益

-1.63M

Pharmala Biotech Holdings Inc., a biotechnology company, engages in the development, manufacture, and sale of MDMA and MDXX class molecules in service to the burgeoning clinical research community. It offers its MDMA drug active pharmaceutical ingredients under the LaNeo brand. The company is headqu... Pharmala Biotech Holdings Inc., a biotechnology company, engages in the development, manufacture, and sale of MDMA and MDXX class molecules in service to the burgeoning clinical research community. It offers its MDMA drug active pharmaceutical ingredients under the LaNeo brand. The company is headquartered in Vancouver, Canada. 詳細を表示

セクター

Healthcare

業界

Biotechnology & Life Sciences

ウェブサイト

pharmala.ca

本社

Vancouver, Canada

設立

PharmAla Biotech Holdings Inc (QB) is listed in the Healthcare sector of the その他OTC with ticker MDXXF. The last closing price for PharmAla Biotech (QB) was US$0.10. Over the last year, PharmAla Biotech (QB) shares have traded in a share price range of US$ 0.0614 to US$ 0.1511.

PharmAla Biotech (QB) currently has 108,887,215 shares in issue. The market capitalisation of PharmAla Biotech (QB) is US$10.87 million. PharmAla Biotech (QB) has a price to earnings ratio (PE ratio) of -9.03.

Micro-Cap Biotech Stocks Surge After Breakthrough Psychedelics Licensing Announcement

The psychedelics market continues to expand rapidly as researchers gain a deeper understanding of its potential therapeutic benefits. Today, a...

PharmAla Biotech Signs Term Sheet for $100 Million U.S. Licensing Deal for ALA-002 MDMA Therapy (MDXXF)

The proposed agreement would grant Jupiter Neurosciences exclusive U.S. rights to PharmAla’s lead psychedelic drug candidate while allowing...

PharmAla Biotech Signs Term Sheet to License Exclusive U.S. Rights to ALA-002, Its Next-Generation MDMA Therapeutic, to Jupiter Neurosciences, Inc. (NASDAQ: JUNS) in a Transaction Valued at Over $100 Million

TORONTO, May 20, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (CSE: MDMA; OTCQB: MDXXF...

Jupiter Neurosciences Secures $100M Term Sheet for Exclusive U.S. Rights to ALA-002, a Next-Generation MDMA Therapeutic from PharmAla Biotech

Transaction Positions JUNS at the Forefront of Next-Generation MDMA-Based Therapeutics Following President...

PharmAla Biotech Executes Definitive Agreement to Form Special Purpose Vehicle, Restora Neurosciences, for Clinical Development of Patented Novel MDXX Molecule APA-01

TORONTO, May 13, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (CSE: MDMA) (OTCQB: MDXXF...

PharmAla Executes Binding Letter of Intent for Formation of Special Purpose Vehicle to Develop Patented Novel MDXX Molecule APA-01

TORONTO, April 27, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (CSE: MDMA)(OTCQB: MDXXF...

PharmAla Issues Q2 Financial Statements and Grants Options

TORONTO, April 21, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”...

PharmAla Biotech Positioned to Supply U.S. Expanded Access Pathway for MDMA Established by Presidential Executive Order

TORONTO, April 20, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (CSE: MDMA)(OTCQB: MDXXF...

Cortexa Advances Commercialisation of MDMA Supply in Australia

MELBOURNE, Australia, March 23, 2026 (GLOBE NEWSWIRE) -- Cortexa (Cortexa or the Company), a leading...

PharmAla Signs Supply & Data Agreement with Nautilus Sanctuary for Phase 2 MDMA Clinical Trial Treating Post-Traumatic Stress and Adjustment Disorder in Frontline Healthcare Workers and First Responders

TORONTO, March 03, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (CSE: MDMA)(OTCQB: MDXXF), a...

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	-0.0002	-0.2	0.1	0.107975	0.0997	4567	0.10047263	CS
4	-0.0172	-14.7008547009	0.117	0.1198	0.0889	30318	0.10828257	CS
12	0.0308	44.6376811594	0.069	0.1511	0.064	64927	0.11603998	CS
26	0.02084	26.3931104357	0.07896	0.1511	0.064	45014	0.11335573	CS
52	0.02049	25.8353297188	0.07931	0.1511	0.0614	36373	0.09881391	CS
156	-0.0502	-33.4666666667	0.15	0.35	0.04005	32904	0.12677405	CS
260	-0.0502	-33.4666666667	0.15	0.35	0.04005	32904	0.12677405	CS